Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A

Cancer Research

Volumn 56, Issue 6, 1996, Pages 1309-1314

  Gupta, Elora ^a   Safa, Ahmad R ^a   Wang, Xiaolin ^a   Ratain, Mark J ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CYCLOSPORIN A; DRUG METABOLITE; GLYCOPROTEIN P; IRINOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILIARY EXCRETION; CANCER CHEMOTHERAPY; CHOLESTASIS; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFECT; GLUCURONIDATION; INTRAHEPATIC BILE DUCT; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PHOTOAFFINITY LABELING; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN MODIFICATION; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BILE; CAMPTOTHECIN; CYCLOSPORINE; FEMALE; P-GLYCOPROTEIN; RATS; RATS, WISTAR;

EID: 0029876561     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Tsuji, T , Kaneda, N., Kado, K , Yokokura, T., Yoshimoto, T., and Tsuru, D. CPT-11 converting enzyme from rat serum: purification and some properties. J. PharmacobioDyn., 14: 341-349, 1991.
2. Atsumi, R., Suzuki, W., and Hakasui, H. Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. Xenobiotica, 21: 1159-1169, 1991
3. Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H , and Sato, K Intracellular roles of SN-38, a metabolite of ehe camptothecin derivative CPT-11, in the anti-tumor effect of CPT-11 Cancer Res., 51: 4187-4191, 1991.
4. Gupta, E., Lestingi, T. M., Mick, R., Ramirez, J., Vokes, E E., and Ratain, M. J. Metabolic fate of innotecan in humans, correlation of glucuronidation with diarrhea. Cancer Res., 54: 3723-3725, 1994.
5. Araki, E., Ishikawa, M , Iigo, I , Koide, T., Itabashi, M., and Hoshi, A. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn. J. Cancer Res., 84: 697-702, 1993.
6. Ikuno, N., Soda H , Watanabe, M., Narasaki, F , Fujino, S., Takatani, H , Oka, M., and Hara, K. CPT-11 causes mucosal changes in the small intestine and the caecum: histopathological analysis in mice. Proc Am. Assoc Cancer Res., 36: 442, 1995.
7. Kaneda, N., and Yokokura, T. Nonlinear pharmacokinencs of CPT-11 in rats. Cancer Res , 50: 1721-1725, 1990.
8. Rothenberg, M L , Kuhn, J. G., Burris, H A., III, Nelson, J., Eckardt, J. R., Tristan-Morales, M., Hilsenbeck, S G., Weiss, G R., Smith, L. S., Rodriguez, G I., Rock, M. K. and Von Hoff, D. D. Phase I and pharmacokinetic trial of weekly CPT-11 J. Clin. Oncol., 11: 2194-2204, 1993.
9. de Forni, M., Bugat, R., Chabot, G. G., Culine, S., Extra, J-M., Gouyette, A., Madelaine, I , Marty, M E., and Mathieu-Boue, A. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan administered on a weekly schedule in cancer patients Cancer Res , 54: 4347-4354, 1994.
10. Lokiec, F., Canal, P , Gay, C., Chatelut, E., Armand, J-P , Roche, H , Bugat, R., Goncalves, E , and Mathieu-Boue, A. Pharmacokinetics of irinotecan and its metabolites in human blood, bile and urine. Cancer Chemother. Pharmacol., 36: 79-82, 1995
11. Klaassen, C D , and Watkins, J. B , III Mechanisms of bile formation, hepatic uptake, and biliary excretion Pharmacol. Rev., 36: 1-67, 1984
12. Le Thai, B., Dumont, A., Michel, A., Erlinger, S., and Haussin, D. Cyclosporine-induced cholestasis, inhibition of bile acid secretion is caused by the parental molecule Transplant. Proc., 19: 4149-4151, 1987.
13. Le Thai, B., Dumont, M., Michel, A , Erlinger, S., and Houssin, D Cholestatic effect of cyclosporine in the rat, an inhibition of bile acid secretion Transplantation (Baltimore), 46: 510-512, 1988
14. Stone, B., Warty, V., Dindzans, V., and Van Thiel, D. The mechanism of cyclosporine-induced cholestasis in the rat. Transplant. Proc., 20: 841-844, 1988.
15. Foxwell, B. M J., Mackie, A , Ling, V., and Ryffel, B. Identification of the multidrug resistance-related P-glycoprotein as a cyclospotine binding protein. Mol. Pharmacol., 36: 543-546, 1989
16. Saeki, T., Ueda, K., Tanigawara, Y , Hori, R., and Komano, T. Human P-glycoprotein transports cyclosporin A and FK 506 J Biol. Chem., 268: 6077-6080, 1993.
17. Tamai, I , and Safa, A. R Competitive interaction of cyclosporins with the Vinca alkaloid-binding site of P-glycoprotein in multidrug resistant cells. J. Biol. Chem., 265 16509-16513, 1990.
18. Kamimoto, Y., Gatmaitan, Z , Hsu, J , and Arias, I M The function of GP170, the multidrug resistance gene product, in rat liver canalicular membrane vesicles. J Biol. Chem., 264: 11693-11698, 1989.
19. Sinicrope, F A., Dudeja, P K., Bissonnette, B. M., Safa, A. R., and Brasitus, T. A. Modulation of P-glycoprotein-mediated drug transport by alterations in lipid fluidity of rat liver canalicular membrane vesicles J. Biol. Chem., 267: 24995-25002, 1992.
20. Vore, M. Canalicular transport: discovery of ATP-dependent mechanisms. Toxicol. Appl. Pharmacol., 118: 2-7, 1993.
21. Schrenk, D , Gant, T. W., Preisegger, K-H , Silverman, J A., Marino, P. A , and Thorgeirsson, S. S. Induction of multidrug resistance gene expression during cholestasis in rats and nonhuman primates. Hepatology, 17: 854-860, 1993.
22. Arias, I. M. Cyclosporin, the biology of the bile canaliculus and cholestasis Gastroenterology, 104: 1558-1559, 1993
23. Bohme, M., Jedlitschky, G., Leier, I., Buchler, M., and Keppler, D. ATP-dependent export pumps and their inhibition by cyclosporins. Adv. Enzyme Resul., 34, 371-380, 1994.
24. Safa, A. R. Photoaffinity labeling of the multidrug-resistance-related P-glycoprotein with photoactive analogs of verapamil. Proc. Natl. Acad. Sci. USA, 85: 7187-7191, 1988.
25. Woodcock, D. M., Jefferson, S., Linsenmeyer, M. E., Crouther, P. J., Chojnowski, G. M., Williams, B., and Bertoncello, I. Reversal of the multidrug resistance phenorype with Cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res., 50: 4199-4203, 1990.
26. Schuurhuis, G. J , Broxterman, H. J., Pinedo, H. M , van Heijningen, T H. M., van Kalken, C K., Vermorken, J. B., Spoelstra, E. C., and Lankelma, J The polyoxyethylene castor oil Cremophor EL modifies multidrug resistance. Br. J. Cancer, 62: 591-594, 1990
27. Sasaki, Y., Yoshida, Y., Sudoh, X., Hakusui, H., Fujii, H., Ohtsu, T., Wakita, H., Igarashi, T., and Itoh, K. Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11. Jpn. J. Cancer Res , 86: 111-116, 1995.
28. Tamai, I., and Safa, A. R. Azidopine noncompetitively interacts with vinblastine and cyclosporin A binding to P-glycoprotein in multidrug resistant cells J. Biol. Chem , 266: 16796-16800, 1991.
29. Yee, G. C., and Salomon, D. R Cyclosporin. In: W. E. Evans, J. J. Schentag, and W. J. Jusko (eds.), Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring, pp. 28-1-28-40. Vancouver, British Columbia: Applied Therapeutics, Inc., 1992.
30. Christians, U., Strohmeyer, S., Kownatzki, R., Schiebel, H-M , Bleck, J , Greipel, J., Kohlhaw, K., Schottmann, R., and Sewing, K-F. Investigations on the metabolic pathways of cyclosporine. I. Excretion of cyclosporin and its metabolites in human bile: isolation of 12 new cyclosporine metabolites. Xenobioncs, 21: 1185-1198, 1991.
31. Christians, U., Strohmeyer, S., Kownatzki, R., Schiebel, H-M., Bleck, J., Kohlhaw, K , Schottmann, R., and Sewing, K-F. Investigations on the metabolic pathways of cyclosporine, II. Elucidation of the metabolic pathways in vitro by human liver microsomes. Xenobiotics, 21: 1199-1210, 1991.
32. Rivory, L P., and Robert, J. Identification and kinetics of a β-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan Cancer Chemother. Pharmacol., 36: 176-179, 1995.
33. Burke, T G., Munshi, C. B , Mi, Z., and Jiang, Y The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs. J. Pharm Sci , 84: 518-519, 1995.
34. Burke, T., Mi, Z., Roy, D , and Munshi, C The pivotal role of albumin in determining the relative blood stabilities of camptothecin analogs presently in clinical trials Proc Am. Soc. Clin. Oncol., 14: 463, 1995.
35. Lindholm, A. Factors influencing the pharmacokinetics of cyclosporine in man. Ther. Drug Monit., 13: 465-477, 1991.
36. Gerlowski, L. E., and Jain, R. K. Physiologically based pharmacokinetic modeling: principles and applications. J. Pharm. Sci., 72: 1103-1127, 1983.
37. Jansenm P. L. M., Peters, W. H., and Lamers, W H. Hereditary chronic conjugated hyperbilirubinemia in mutant rats caused by defective hepatic anion transport. Hepatology, 5: 573-579, 1985.
38. - rats, with conjugated hyperbilirubinemia. Proc. Natl Acad Sci. USA, 87: 3557-3561, 1990
39. Kadmon, M., Klunemann, C., Bohme, M., Ishikawa, T , Gorgas, K., Otto, G., Herfarth, C., and Keppler, D Inhibition by cyclosporin A of adenosine triphosphate-dependent transport from the hepatocyte into bile. Gastroenterology, 14: 1507-1514, 1993
40. Bohme, M., Muller, M., Leier, L. Jedlitschky, G., aad Keppler, D. Cholestasis caused by inhibition of the adenosine triphosphate-dependent bile salt transport in rat liver. Gastroenterology, 107: 255-265, 1994
41. Yahanda, A M , Adler, K. M., Fisher, G. A., Brophy, N. A., Halsey, J , Hardy, R. I., Gosland, M P , Lum, B. L., and Sikic, B. I. Phase I trial of etoposide with cyclosporine as a modulator of muludrug resistance. J. Clin. Oncol., 10: 1624-1634, 1992.
42. Samuels, B L , Mick, R., Vogelzang, N J., Williams, S. F., Schilsky, R. L., Safa, A. R., O'Brien, S. M., and Ratain, M J. Modulation of vinblastine resistance with cyclosporine, a Phase I study Clin Pharmacol. Ther. 54: 421-429, 1993.
43. Batalla, A., Malmary, M. F , Cambar, J., Labat, C., and Oustrin, J Dosing time-dependent nephrotoxicity of cyclosporin A during 21-day administration to Wistar rats Chronobiol. Int., 11: 187-195, 1994.